Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors
Yazarlar (16)
Yucel Erbilgin
Istanbul Üniversitesi, Türkiye
Ahmet Emre Eskazan
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Ozden Hatirnaz Ng
Istanbul Üniversitesi, Türkiye
Ayse Salihoglu
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Tugrul Elverdi
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Sinem Firtina
Istanbul Üniversitesi, Türkiye
Orcun Tasar
Istanbul Üniversitesi, Türkiye
Dr. Öğr. Üyesi Sevcan MERCAN
Kafkas Üniversitesi, Türkiye
Sinem Sisko
Istanbul Üniversitesi, Türkiye
Khusan Khodzhaev
Istanbul Üniversitesi, Türkiye
Seniz Ongoren
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Muhlis Cem Ar
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Zafer Baslar
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Teoman Soysal
İstanbul University-Cerrahpaşa Cerrahpaşa Faculty Of Medicine, Türkiye
Muge Sayitoglu
Istanbul Üniversitesi, Türkiye
Ugur Ozbek
Istanbul Üniversitesi, Türkiye
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Leukemia and Lymphoma | ||
| Dergi ISSN | 1042-8194 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 12-2018 |
| Cilt / Sayı / Sayfa | 60 / 1 / 200–207 | DOI | 10.1080/10428194.2018.1473573 |
| Makale Linki | https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1473573 | ||
| Özet |
| Tyrosine kinase inhibitor (TKI) therapy is the current treatment of choice for patients with chronic phase chronic myeloid leukemia (CML) leading to rapid and durable hematological as well as molecular responses. However, emergence of resistance to TKIs has been the major obstacle to treatment success on long term. In this regard kinase domain mutations are the most common mechanism of therapy failure. In this study, we analyzed peripheral blood samples from 17 CML patients who had developed resistance to various TKIs by using next-generation sequencing parallel to Sanger sequencing. BCR-ABL1 kinase domain mutations have been found in 59% of the cohort. Our results demonstrate that next-generation sequencing results in a higher mutational detection rate than reported with conventional sequencing methodology. Furthermore, it showed the clonal diversity more accurately. |
| Anahtar Kelimeler |
| Chronic myeloid leukemia | drug resistance | next-generation sequencing | tyrosine kinase inhibitor |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| SCOPUS | 15 |
| Google Scholar | 22 |